|
US2020000758A1
|
|
Oral Dosage Forms Of Methyl Hydrogen Fumarate And Prodrugs Thereof
|
|
WO2016182898A1
|
|
Methods of use for monomethyl fumarate and prodrugs thereof
|
|
WO2016061393A1
|
|
Fumarate compounds, pharmaceutical compositions, and methods of use
|
|
US2015265707A1
|
|
Pharmaceutical compositions of fumaric acid esters
|
|
WO2015042294A1
|
|
Nanoparticle compositions of dimethyl fumarate
|
|
WO2015035184A1
|
|
Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
|
|
CA2919381A1
|
|
Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
|
|
US2014378542A1
|
|
Cocrystals of dimethyl fumarate
|
|
WO2014197860A1
|
|
Method of making monomethyl fumarate
|
|
US2014284245A1
|
|
Pharmaceutical compositions of dimethyl fumarate
|
|
WO2014134005A2
|
|
Method of making 1-(acyloxy)-alkyl carbamate compounds
|
|
WO2014071371A1
|
|
Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
|
|
AU2013237675A1
|
|
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
|
|
WO2014031844A1
|
|
Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
|
|
US2014056978A1
|
|
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
|
|
WO2014031901A1
|
|
Methods of use for monomethyl fumarate and prodrugs thereof
|
|
WO2014143146A1
|
|
Methods of administering monomethyl fumarate
|
|
WO2013181451A1
|
|
Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate
|
|
US2013184344A1
|
|
Levodopa prodrug mesylate hydrate
|
|
EP2812319A1
|
|
Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
|
